Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
For cisplatin-ineligible pT4N0M0 renal pelvis UTUC without prior neoadjuvant therapy, do you prefer adjuvant carboplatin/gemcitabine (POUT) or immunotherapy (CheckMate 274)?
Related Questions
What would be your recommended regimen for an AYA patient with relapsed mediastinal pure seminoma, with relapse 20 months after completion of BEP?
If approved, how will you choose between Disitamab Vedotin/Toripalimib (DV+T) and EV+Pembro (EV-303), in those patients with HER2+ mUC?
Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?
For patients with modest hyperbilirubinemia (Tbili 2-3) due to chronic liver disease, but otherwise normal liver indices, would you consider still utilizing enfortumab vedotin for metastatic urothelial carcinoma?
How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
When considering cytoreductive nephrectomy in metastatic kidney cancer, in which situations would you consider nephron-sparing approaches such as partial nephrectomy or SBRT?
What are your top takeaways in GU Cancers from ESMO 2025?
What are your top takeaways from ASCO GU 2025?
For patients with high-volume hormone-sensitive prostate cancer, would you consider shortening the docetaxel course to 4 cycles to facilitate better tolerance?
